Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL27442310 | 1.00 | NAPRT (0.39) | NAPRTTDP1LMNAPTGS2CA2 | |
| Pyrimidine SCHEMBL6216525 | 0.88 | KDM4E (0.40) | NAPRTTDP1PTGS2TSHR | |
| Pyrimidine SCHEMBL21056190 | 0.88 | NAPRT (0.42) | NAPRTTDP1TSHR | |
| Pyrimidine SCHEMBL389598 | 0.88 | NAPRT (0.42) | NAPRTTDP1TSHR | |
| Pyrimidine SCHEMBL29040951 | 0.88 | NAPRT (0.42) | NAPRTTDP1TSHR | |
| Pyrimidine SCHEMBL9322876 | 0.88 | NAPRT (0.42) | NAPRTTDP1TSHR | |
| Pyrimidine SCHEMBL27984552 | 0.85 | NAPRT (0.41) | NAPRTTDP1TSHR | |
| Pyrimidine SCHEMBL22711662 | 0.85 | NAPRT (0.41) | NAPRTTDP1TSHR | |
| Pyridine SCHEMBL10678990 | 0.82 | NAPRT (0.53) | NAPRTTDP1LMNAPTGS2CA2 | |
| Pyrimidine SCHEMBL11689582 | 0.82 | CA1 (0.47) | NAPRTTDP1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100422186-C | Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same | ONO PHARMACEUTICAL CO (JP) | 2008-10-01 | — | — | CN | claimed |
| CN-1842530-A | Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same | ONO PHARMACEUTICAL CO (JP) | 2006-10-04 | — | — | CN | claimed |
| CN-1152022-C | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | �������Ŷ���Լ��������˾ | 2004-06-02 | — | — | CN | claimed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-109890846-A | anti-CD 27 antibodies | 默沙东公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-109081815-A | A kind of preparation method of novel electrophilic reagent methanesulfonic acid pyrimidine ester | 甘肃农业大学 | 2018-12-25 | — | — | CN | disclosed |
| CN-108676800-A | The inhibition led using the mediated rnai of hepatitis type B virus (HBV) gene expression of short interfering nucleic acid (siNA) | 瑟纳治疗公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-103282497-B | RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-105050598-B | Novel compounds as ERK inhibitors | 默沙东公司 | 2018-04-27 | — | — | CN | disclosed |
| CN-107245075-A | Simultaneously [3,4 d] pyrimidines and its salt and the application of 2,4,6 3 substituted pyridines | 西安交通大学 | 2017-10-13 | — | — | CN | disclosed |
| CN-105073746-B | Substituted imidazopyridines as HDM2 inhibitors | 默沙东公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-1535958-A | Alpha-substituted pyrimidine. thioalkyl and alkyl ether compound | �������Ŷ���Լ��������˾ | 2004-10-13 | — | — | CN | disclosed |
| CN-1152022-C | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | �������Ŷ���Լ��������˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1493291-A | Dicyclic compound capable of inhibiting epidermis growth factor acceptor rotatory tyrosine kinase | ��ʲ | 2004-05-05 | — | — | CN | disclosed |
| CN-1140269-C | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | ��ʲ | 2004-03-03 | — | — | CN | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| CN-1227560-A | Thienopyrimidines | MERCK PATENT GMBH (DE) | 1999-09-01 | — | — | CN | disclosed |
| CN-1183773-A | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | UPJOHN CO (US) | 1998-06-03 | — | — | CN | disclosed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| CN-1071925-A | New 3-(replacement tetrazyl)-4-oxo-4H-pyrido [1,2-a] pyrimidine, their salt contains their pharmaceutical composition and preparation method thereof | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1993-05-12 | — | — | CN | disclosed |